Protein kinase G transmits the cardioprotective signal from cytosol to mitochondria

被引:239
作者
Costa, ADT
Garlid, KD
West, IC
Lincoln, TM
Downey, JM
Cohen, MV
Critz, SD
机构
[1] Univ S Alabama, Coll Med, Dept Cell Biol & Neurosci, Mobile, AL 36688 USA
[2] Univ S Alabama, Dept Physiol, Mobile, AL 36688 USA
[3] Univ S Alabama, Dept Med, Mobile, AL 36688 USA
[4] Portland State Univ, Dept Biol, Portland, OR 97207 USA
关键词
ATP-sensitive K+ channel; cGMP; preconditioning; protein kinase C; protein kinase G;
D O I
10.1161/01.RES.0000178451.08719.5b
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Ischemic and pharmacological preconditioning can be triggered by an intracellular signaling pathway in which G(i)-coupled surface receptors activate a cascade including phosphatidylinositol 3-kinase, endothelial nitric oxide synthase, guanylyl cyclase, and protein kinase G (PKG). Activated PKG opens mitochondrial K-ATP channels ( mitoKATP) which increase production of reactive oxygen species. Steps between PKG and mitoK(ATP) opening are unknown. We describe effects of adding purified PKG and cGMP on K+ transport in isolated mitochondria. Light scattering and respiration measurements indicate PKG induces opening of mitoK(ATP) similar to K-ATP channel openers like diazoxide and cromakalim in heart, liver, and brain mitochondria. This effect was blocked by mitoK(ATP) inhibitors 5-hydroxydecanoate, tetraphenylphosphonium, and glibenclamide, PKG-selective inhibitor KT5823, and protein kinase C (PKC) inhibitors chelerythrine, Ro318220, and PKC-epsilon peptide antagonist epsilon V1-2. MitoK(ATP) are opened by the PKC activator 12-phorbol 13-myristate acetate. We conclude PKG is the terminal cytosolic component of the trigger pathway; it transmits the cardioprotective signal from cytosol to inner mitochondrial membrane by a pathway that includes PKC-epsilon.
引用
收藏
页码:329 / 336
页数:8
相关论文
共 44 条
[11]  
GARLID KD, 1985, J BIOL CHEM, V260, P3434
[12]   The mitochondrial K-ATP channel as a receptor for potassium channel openers [J].
Garlid, KD ;
Paucek, P ;
YarovYarovoy, V ;
Sun, XC ;
Schindler, PA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (15) :8796-8799
[13]  
GORNALL AG, 1949, J BIOL CHEM, V177, P751
[14]   A selective ε-protein kinase C antagonist inhibits protection of cardiac myocytes from hypoxia-induced cell death [J].
Gray, MO ;
Karliner, JS ;
Mochly-Rosen, D .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (49) :30945-30951
[15]   Inhibition of protein kinase C mu by various inhibitors. Differentiation from protein kinase c isoenzymes [J].
Gschwendt, M ;
Dieterich, S ;
Rennecke, J ;
Kittstein, W ;
Mueller, HJ ;
Johannes, FJ .
FEBS LETTERS, 1996, 392 (02) :77-80
[16]   Additive protection of the ischemic heart ex vivo by combined treatment with δ-protein kinase C inhibitor and ε-protein kinase C activator [J].
Inagaki, K ;
Hahn, HS ;
Dorn, GW ;
Mochly-Rosen, D .
CIRCULATION, 2003, 108 (07) :869-875
[17]  
Jaburek M, 1998, J BIOL CHEM, V273, P13578
[18]   A protein kinase C translocation inhibitor as an isozyme-selective antagonist of cardiac function [J].
Johnson, JA ;
Gray, MO ;
Chen, CH ;
MochlyRosen, D .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (40) :24962-24966
[19]   Infarct size limitation by bradykinin receptor activation is mediated by the mitochondrial but not by the sarcolemmal KATP channel [J].
Kita, H ;
Miura, T ;
Miki, T ;
Genda, S ;
Tanno, M ;
Fukuma, T ;
Shimamoto, K .
CARDIOVASCULAR DRUGS AND THERAPY, 2000, 14 (05) :497-502
[20]   Protection of cardiac mitochondria by diazoxide and protein kinase C: Implications for ischemic preconditioning [J].
Korge, P ;
Honda, HM ;
Weiss, JN .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (05) :3312-3317